Spark's price for Luxturna blindness gene therapy too high: ICER

(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Spark's price for Luxturna blindness gene therapy too high: ICER

(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that ...

Fri 12 Jan 18 from Reuters

Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER, Fri 12 Jan 18 from Reuters

  • Pages: 1

Bookmark

Bookmark and Share